Zonjero – Tirzepatide Research Peptide Pen (30mg / 3ml)
All products are shipped in a cooler box at the appropriate temperature.
What is Tirzepatide?
Tirzepatide is a first-in-class dual GLP-1 / GIP (glucagon-like peptide-1 / glucose-dependent insulinotropic polypeptide) receptor agonist — a groundbreaking synthetic peptide that simultaneously engages two of the body’s most important incretin signaling pathways. Engineered with a balanced affinity profile and an advanced fatty diacid side chain for exceptional pharmacokinetic stability, tirzepatide achieves a half-life of approximately 5 days, supporting once-weekly administration across research protocols.
Zonjero delivers laboratory-grade tirzepatide (>99% purity, third-party COA verified) in a high-capacity, ready-to-use 30mg / 3ml pre-filled pen — the gold-standard dual incretin research tool for investigating synergistic GLP-1 and GIP receptor signaling, profound metabolic remodeling, and superior body weight regulation.
What are the benefits of Tirzepatide in research?
Tirzepatide’s unique dual-agonist mechanism produces a synergistic effect that consistently outperforms single GLP-1 receptor agonists across multiple research domains. Key areas of investigational interest include:
- Synergistic insulin secretion & glucagon suppression: By activating both GLP-1 and GIP receptors simultaneously, tirzepatide produces enhanced glucose-dependent insulin secretion and robust glucagon suppression — an effect that exceeds what either pathway achieves independently.
- Appetite suppression: Tirzepatide exerts powerful appetite-reducing effects through both central and peripheral mechanisms, consistently demonstrating substantial reductions in caloric intake across research models.
- Gastric emptying & satiety: The compound delays gastric emptying and prolongs satiety signaling, contributing to reduced food consumption and improved postprandial glucose management in investigational settings.
- Body weight modulation: Tirzepatide has produced some of the most significant weight reduction findings ever recorded in clinical-phase metabolic research, with mean body weight losses of 20–25% frequently reported at higher doses over 72-week study periods.
- Insulin sensitivity & glycemic control: Research has consistently demonstrated tirzepatide’s superiority over single GLP-1 agonists in improving insulin sensitivity and overall glycemic regulation across a range of experimental models.
- Visceral fat & liver health: Tirzepatide investigations have documented significant reductions in visceral adipose tissue and liver fat content, alongside meaningful improvements in markers of metabolic inflammation and metabolic dysfunction-associated steatotic liver disease.
- Cardiometabolic profile: Study findings have shown favorable shifts in lipid parameters, blood pressure, and broader cardiovascular risk markers, establishing tirzepatide as a compound of strong interest for cardiometabolic research.
Clinical Research & Trial Results
Tirzepatide has been the subject of a comprehensive and high-profile clinical research program, with results that have set new benchmarks across the incretin-based compound class. Phase 3 investigations have repeatedly confirmed tirzepatide’s dual-incretin mechanism delivers outcomes markedly superior to those observed with established GLP-1 receptor agonists alone.
Across multiple large-scale studies, participants receiving higher tirzepatide doses achieved mean body weight reductions frequently in the range of 20–25% over 72 weeks — findings that have redefined expectations for investigational metabolic compounds. Additional trial data have confirmed substantial improvements in HbA1c, fasting glucose, lipid profiles, blood pressure, and liver fat content. The compound’s engineered fatty diacid conjugation provides the pharmacokinetic stability underpinning its extended half-life of approximately 5 days, making it well-suited to once-weekly research administration schedules.
Proper Usage & Dosage Guidelines
The dosage and administration of tirzepatide for research purposes should be determined in accordance with the specific experimental protocol in use. Zonjero is administered via subcutaneous injection, with tirzepatide’s extended half-life of approximately 5 days supporting once-weekly dosing in research settings.
Pen Specifications – Zonjero 30mg / 3ml Pen:
The Zonjero pen contains 30mg of tirzepatide in 3ml solution (10mg/ml concentration), offering generous dosing flexibility for longer-term protocols, dose-escalation studies, or experiments requiring higher compound exposure levels.
Additional Usage Notes:
- Inject into the abdomen area or the front of the thigh
- After injecting, wait 10 seconds before removing the needle
- Rotate injection sites between administrations
- Store refrigerated at all times; do not freeze
- Use sterile, single-use needles only — replace with each injection
Possible Side Effects
Consistent with the GLP-1 receptor agonist class, tirzepatide research has identified a well-characterized side effect profile. The most commonly observed effects include nausea, vomiting, diarrhea, constipation, and mild discomfort at the injection site. These effects are most frequently associated with initial dosing or dose-escalation phases and typically diminish as administration continues at a stable dose.
Adherence to established dosing and escalation protocols remains the most effective approach to minimizing adverse responses across research settings.
What’s Included
- Reusable precision peptide pen injector
- Pre-filled Zonjero (tirzepatide) solution — 30mg / 3ml
- Detailed usage instructions
- 10 sterile, single-use needles
Why Choose Zonjero?
Zonjero is manufactured in certified laboratories to deliver tirzepatide at greater than 99% purity, independently confirmed by third-party certificate of analysis. The sterile, ready-to-use pre-filled pen format offers precise delivery and maximum convenience for research applications. The high-capacity 30mg / 3ml configuration ensures ample supply for extended protocols, dose-escalation studies, and complex experimental designs — all backed by tirzepatide’s advanced molecular engineering for prolonged activity and stability.
Lead the forefront of dual-incretin science with Zonjero — where GLP-1 + GIP synergy delivers some of the most dramatic metabolic effects currently under investigation.
The information presented has been collected from published studies and analyses and is not intended for diagnosing, treating, or preventing any disease.
Notice: Zonjero (tirzepatide) is supplied strictly and exclusively for in-vitro laboratory research, scientific study, and analytical use only. It is not approved as a drug, food, supplement, or compound for human consumption, therapeutic use, diagnosis, or treatment in humans or animals. The purchaser accepts full responsibility for proper handling, refrigerated storage, legal compliance, and adherence to all applicable institutional, national, and international regulations.
Reviews
There are no reviews yet.